The ALIGN-AR trial contributes to the literature by demonstrating high technical success, a reassuring safety profile, and favorable clinical outcomes in high-risk patients with aortic regurgitation ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

"Refocusing and reframing the definition and discussion of coronary artery disease (CAD) from late-stage ischemia and acute coronary events to early detection of coronary artery atheroma and ...

The novel extended-duration small interfering RNA lepodisiran reduced mean serum concentrations of lipoprotein(a) (Lp[a]) from 60 to 180 days after being administered subcutaneously, according to ...

Coronary atherosclerotic phenotypes, including total plaque volume (TPV), noncalcified plaque (NCP), calcified plaque (CP) and percentage atheroma volume (PAV), assessed by artificial ...

The ZENITH trial demonstrated that among high-risk adults with PAH on maximum tolerated dose of background therapy, treatment with sotatercept resulted in a lower risk of all-cause death, lung ...

In sharp contrast to earlier studies, patients with severe triple-vessel heart disease fared equally well whether they underwent open-heart bypass surgery (CABG) or a less invasive procedure called ...

One of the most significant modifications that middle-aged patients can take to prevent cardiovascular disease is lowering arterial hypertension, according to research presented during a Featured ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

The overall survival rate of athletes who suffer sudden cardiac arrest has improved over the past decade, but the likelihood of surviving varies by race, where the cardiac arrest occurred and what ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...

The HERZCHECK trial demonstrates the feasibility and diagnostic value of a mobile, CMR-based screening strategy for detecting asymptomatic stage B HF in rural, high-risk populations. Participants in ...